Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation

The Washington University

Status and phase: Completed; Phase 2

Conditions: Antibody-mediated Rejection; Lung Transplant Rejection

Treatments: Drug: Mycophenolate Mofetil; Drug: Prednisone; Drug: Tacrolimus; Drug: ATG; Drug: Belatacept; Drug: Methylprednisolone

Study type: Interventional

Funder types: Other; Industry; NIH

Identifiers

NCT03388008

Bela Lung Pilot

Details and patient eligibility

About

This is a pilot randomized controlled trial examining the feasibility of conducting a large scale randomized controlled trial of belatacept-based immunosuppression in lung transplantation. This pilot study will enroll 40 lung transplant recipients and randomize them to belatacept-based immunosuppression or standard of care. The primary endpoint of the study is the development of donor-specific HLA antibodies after transplantation. All study participants will be followed for a minimum of 12 months after transplantation.

Full description

Lung transplantation is the ultimate treatment for patients with advanced lung disease. However, long-term outcomes remain disappointing and the median survival after transplantation is approximately 5.5 years. Beyond the first year after transplantation, chronic lung allograft dysfunction is the leading cause of death. The exact mechanisms that lead to chronic lung allograft dysfunction are unclear, but the development of donor-specific HLA antibodies is an independent risk factor. In fact, studies have consistently identified the development of donor-specific HLA antibodies as a significant and independent risk factor for chronic lung allograft dysfunction and mortality after transplantation.

Belatacept is a CTLA4-Ig fusion protein that binds CD80 and CD86 thereby blocking CD28 co-stimulatory signals. Belatacept has been extensively studied in kidney transplantation. In a long-term study, patients treated with Belatacept had better survival than those treated with Cyclosporine. Importantly, Belatacept-treated patients were significantly less likely to develop donor-specific HLA antibodies than Cyclosporine-treated patients. Nonetheless, Belatacept has not been formally evaluated after lung transplantation. The investigators hypothesize that Belatacept-based immunosuppression would result in a lower incidence of donor-specific HLA antibodies and that this would result in better chronic lung allograft dysfunction-free survival after transplantation. Before conducting a large scale randomized controlled trial to test this hypothesis, the investigators plan to conduct the current pilot randomized controlled trial to examine the feasibility of conducting the large scale randomized controlled trial.

The investigators plan to enroll and randomize 40 lung transplant recipients at 2 sites. All recipients will be treated with anti-thymocyte globulin for induction immunosuppression. Those randomized to standard of care immunosuppression will be treated with Tacrolimus, Mycophenolate mofetil, and prednisone. Those randomized to Belatacept-based immunosuppression will be treated with Belatacept, Tacrolimus, and prednisone for the first 89 days; on day 90, Mycophenolate mofetil will be substituted for Tacrolimus and patients will be continued on Belatacept, Mycophenolate mofetil, and prednisone for the remainder of year 1 after transplantation.

Patients in both groups will be monitored closely for episodes of acute cellular rejection, lymphocytic bronchiolitis, and antibody-mediated rejection with surveillance bronchoscopy and transbronchial lung biopsies on days 28, 84, 112, 168, 252, and 365 (± 7 days) as part of the sites' routine clinical protocols. In addition, patients will be monitored for the development of donor-specific HLA antibodies with routine blood tests on on days 10 (± 3 days), 28, 56, 84, 112, 168, 252, and 365 (± 7 days).

The primary endpoint of the study is a composite of the development of donor-specific HLA antibodies, re-transplantation, and death. Secondary endpoints include acute cellular rejection, lymphocytic bronchiolitis, antibody-mediated rejection, chronic lung allograft dysfunction, survival, cytomegalovirus infection, bacterial infection, community-acquired respiratory viral infection, chronic kidney disease stage 3, malignancy, hypertension, diabetes, and hypercholesterolemia.

Enrollment: 27 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provided written informed consent for study participation
• Underwent single or bilateral lung transplantation
• Negative urine pregnancy test for women of child bearing potential and willingness to use highly-effective contraception

Exclusion criteria

• Requiring invasive mechanical ventilation immediately before transplantation
• Requiring extracorporeal life support (ECLS) (i.e., ECMO) immediately before transplantation
• Received treatment to deplete HLA antibodies before transplantation to improve the possibility of transplantation
• Having DSA immediately before transplantation (i.e., positive virtual crossmatch)
• Listed for multi-organ transplant (e.g., heart-lung, liver-lung, kidney-lung)
• Pregnant or breast-feeding
• Active infection with Hepatitis B or C virus
• Active infection with human immunodeficiency virus (HIV)
• Chronic infection with Burkholderia cepacia complex before transplantation
• Epstein Barr Virus (EBV) seronegative status
• Participation in another interventional clinical trial
• Allograft dysfunction requiring ECMO support after transplantation
• Delayed chest closure after transplantation
• Severe coagulopathy and significant bleeding in the opinion of the PI
• Any condition that in the opinion of the site PI introduces undue risk by participating in this study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

27 participants in 2 patient groups

Standard of care

Active Comparator group

Description:

Tacrolimus + Mycophenolate mofetil + prednisone from day 0 through day 365

Treatment:

Drug: Methylprednisolone

Drug: ATG

Drug: Prednisone

Drug: Tacrolimus

Drug: Mycophenolate Mofetil

Belatacept-based immunosuppression

Experimental group

Description:

Belatacept + Tacrolimus + prednisone from day 0 through day 89, then Belatacept + Mycophenolate mofetil + prednisone from day 90 through day 365

Treatment:

Drug: Methylprednisolone

Drug: Belatacept

Drug: ATG

Drug: Prednisone

Drug: Mycophenolate Mofetil